Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. - Wikidata - wikimedia - TriplyDB

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

http://www.wikidata.org/entity/Q46796397

about

Antiangiogenic therapy for high-grade glioma High-grade glioma management and response assessment-recent advances and current challenges Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy Immune Evasion Strategies of Glioblastoma Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma A Systematic Review on the Characteristics, Treatments and Outcomes of the Patients with Primary Spinal Glioblastomas or Gliosarcomas Reported in Literature until March 2015 VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside Advances in the treatment of newly diagnosed glioblastoma Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction Bevacizumab for glioblastoma Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis Nonsurgical treatment of recurrent glioblastoma Targeting Aggressive Cancer Stem Cells in Glioblastoma Combining radiotherapy with sunitinib: lessons (to be) learned Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges Immunotherapy advances for glioblastoma Medical management of brain tumors and the sequelae of treatment.Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status Polymeric drug delivery for the treatment of glioblastoma Ephs and Ephrins in malignant gliomas Trial watch: Dendritic cell-based anticancer therapy To what extent will 5-aminolevulinic acid change the face of malignant glioma surgery?Movement of magnetic nanoparticles in brain tissue: mechanisms and impact on normal neuronal function Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.Therapeutic Potential of Curcumin for the Treatment of Brain Tumors Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Prospects of immune checkpoint modulators in the treatment of glioblastoma Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs What next for newly diagnosed glioblastoma?The Role of Glucose Modulation and Dietary Supplementation in Patients With Central Nervous System Tumors Heat shock protein vaccines against glioblastoma: from bench to bedside Influence of glioblastoma contact with the lateral ventricle on survival: a meta-analysis Self-assembled 20-nm (64)Cu-micelles enhance accumulation in rat glioblastoma

P2860

Q24193485-3A7CD5CD-B5C5-4291-8216-0232971FC876 Q26740664-32A8D3C7-D84B-4DED-8D21-E2DF1CAB5BE7 Q26742107-90D352C3-F4AF-48E1-8B1E-FF9CF37A0D15 Q26765855-9E486F75-E735-45E0-B43B-9869039CFE89 Q26767169-73E9E81E-8558-4CDB-9E89-7820E6882B1F Q26767359-1090653F-5FB2-41A5-BDDD-77DE10E41BF1 Q26770678-D732873A-B571-4F35-928E-F9BB04A1C1E8 Q26773514-5516E22B-9743-4CD7-AD6F-FCE4D95DB0A9 Q26774717-4758BA37-692B-45B7-94D2-709ACB11C56E Q26776307-FB1B0BE0-9109-4EC8-AE94-C49339E21C47 Q26779221-087A60F0-2B3E-453B-8864-32AD4AA6C9EA Q26783779-A865681F-ABB8-4670-8E05-CF4D8D6F1BDB Q26795560-F4DB3615-F2D9-4996-AB62-FEB4A218D900 Q26799983-2AE9D069-36D2-40A8-864F-E1A335F27F4D Q26800587-B3F7D42E-3C11-419A-A324-1225CACAD878 Q26801351-3638729E-AA32-4A50-9F65-D240925F3619 Q26822717-394EDD88-8B32-4BDB-96E7-5CB74817C9C3 Q26824777-F79E852C-09C6-4DDF-927C-4BEFF8C76C40 Q26830388-D01BC7AD-CF1E-4565-8981-8FC90FBD4B23 Q26853308-DA095DAA-726D-49F4-815D-AFCBBDE0524B Q26862516-7A78C2C5-3263-4D01-92EB-AD9CEB716744 Q26866513-D4ED42D4-A622-485E-814B-D0AE368637CD Q26992174-77AF9F01-055E-46F6-90CC-AE0DC7A80F57 Q26998111-E38643B2-F046-4529-83E9-7FB25E00B5F9 Q27001560-723AD0AF-A8EF-4438-A82C-B5B10F5CF875 Q27010046-9E14308D-1925-443A-8F5D-E56E18929791 Q27015780-2173EC48-F4E4-49DF-9721-18BF6F1309E6 Q27024047-45805850-7F0A-4C71-BEB6-E7FD1AE5056E Q27028189-FC1E2A0F-153F-4EF8-9860-C0AAF96060A0 Q27308522-820EB7CB-7DC8-4923-9EE3-A16D6AD6999C Q27853219-791F1987-FBAA-496B-B67A-647159983EAD Q28071572-30996754-E640-4C9D-863B-AB679620C501 Q28078539-3E9DAF90-8601-4ECB-9CDE-D4607F52FC4A Q28081371-36B4B8BE-97C2-42DA-BEE8-345C1B76B463 Q28082603-133755C2-B702-4871-8C5D-0FBA77AF6F63 Q28086839-73F6FAAA-6FEB-4041-AF8F-516059EC7CD7 Q28087476-38B84A35-ACEB-416D-B1F3-E9EA0CA5E3CA Q28087775-D8E5B855-3A7D-485E-AACD-A41E230FB51A Q28278674-1D90F0EC-8D09-4D69-94F8-ADF2A238E1A0 Q28603646-D1FA69B9-0388-434D-A61F-C4161165A903

P2860

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

http://www.wikidata.org/entity/Q46796397

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

@en

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

@nl

type

label

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

@en

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

@nl

prefLabel

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

@en

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

@nl

P1433

Q46796397-0A6E1864-8F90-4860-A4E7-F5847D3F6E3C

P1476

Q46796397-39242735-9275-4C62-86D4-B7C08911898B

P2093

Q46796397-1EE7DD60-FD4C-4B7F-A175-0FD02AE0C946

Q46796397-33495097-1F6C-49BE-82AD-FF85CCD53A68

Q46796397-6398ED81-5828-4E6A-987D-1CFD23B220DF

Q46796397-676A6E7C-B4FF-45BA-8CC9-50E7A4EF48CF

Q46796397-B40E8100-26AE-4F83-81DE-60A84E749085

Q46796397-B9517AEB-59C0-444D-AB05-44F2207166F4

Q46796397-C17763AE-C0FB-4FA5-B82D-DF336370D2A9

Q46796397-CD2E28C0-5AD1-482F-8AB6-ECBE332BFB2B

Q46796397-D4F0B2E3-EBB1-4A4F-B16F-E4CCF5B80512

Q46796397-EC741796-92B8-4269-9CD4-EC8195ABAF1D

P304

Q46796397-CDA5D240-06AB-406F-B857-2570B803EF45

P31

Q46796397-6BCBC0DF-B9B7-4982-9D77-F574FD4EF68F

P356

Q46796397-774993EC-4A88-47CB-B77B-8617A9DCE24B

P407

Q46796397-B3298FBE-8D86-4B21-9053-2B60607CF058

P433

Q46796397-49169656-6218-40FD-812C-30DDAEBC82BF

P478

Q46796397-2EF2077A-7435-4587-9DD6-D3ECE2003EAB

P50

Q46796397-57C4C064-64FB-4378-99E6-9B6BD94C06F7

Q46796397-CDBEF0F9-06E5-4565-9DDB-684A30B7E8EC

Q46796397-E029F67C-0B23-4CCD-A76D-9D58D3FD00B4

P577

Q46796397-2AA5948A-E2A7-4097-ACD7-30EE66407A5B

P698

Q46796397-31C096FF-AF5F-4DE6-B738-325C53501CD4

P921

Q46796397-4B5E1AB2-1CD3-4875-835C-584116AEF45E

Q46796397-E3D5B071-ED80-4718-B37A-AC295D6CB6E4

P356

P1433

The New England Journal of Medicine

P1476

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

@en

P2093

Antoine F Carpentier

http://www.w3.org/2001/XMLSchema#string

Dana Cernea

http://www.w3.org/2001/XMLSchema#string

Frank Saran

http://www.w3.org/2001/XMLSchema#string

Khe Hoang-Xuan

http://www.w3.org/2001/XMLSchema#string

Lauren Abrey

http://www.w3.org/2001/XMLSchema#string

Magalie Hilton

http://www.w3.org/2001/XMLSchema#string

Petr Kavan

http://www.w3.org/2001/XMLSchema#string

Roger Henriksson

http://www.w3.org/2001/XMLSchema#string

Ryo Nishikawa

http://www.w3.org/2001/XMLSchema#string

Timothy Cloughesy

http://www.w3.org/2001/XMLSchema#string

P304

709-722

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1308345

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P50

Alba A. Brandes

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24552318

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy